DOCKET NO.: TJU-2415

PATENT

In Re Application of:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

AUG 17 2001

TECH CENTER 1600/2900

Scott A. Waldman, et al.

Serial No.: 09/819,248

Group Art Unit: 1645

Examiner: Not Yet Assigned

Filing Date: March 27, 2001 USE OF EXPRESSION PROFILING FOR IDENTIFYING MOLECULAR

MARKERS USEFUL FOR DIAGNOSIS OF METASTATIC CANCER

HEREBY CERTIFY THAT THE PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, DC 20231.

Ellen M. Klann REGISTRATION NO.: 44,836

Assistant Commissioner for Patents Washington DC 20231

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

 \boxtimes In accordance with §1.97(b), since this Information Disclosure Statement is being

filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first office action after the filing of request for continued examination under §1.114, no additional fee is required.

	In accordance with §1.129(a), this Information Disclosure Statement is being						
	filed in connection with \square the first or \square second After Final Submission,						
	therefore:						
<u>t</u>	☐ Certification in Accordance with §1.97(e) is attached; or						
	The fee of $$180.00$ as set forth in $$1.17(p)$ is attached.						
	In accordance with §1.97(c), this Information Disclosure Statement is being filed						
	after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or before an action that otherwise closes prosecution in the application, therefore:						
	Certification in Accordance with §1.97(e) is attached; or						
	The fee of $$180.00$ as set forth in $$1.17(p)$ is attached.						
	In accordance with §1.97(d), this Information Disclosure Statement is being filed						
	after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); and the submission fee of §180.00 as set forth in §1.17(p).						
\boxtimes	Copies of each of the references listed on the attached Form PTO-1449 are						
	enclosed herewith.						
	Copies of references listed on the attached Form PTO-1449 are enclosed herewith						
	EXCEPT THAT:						
	☐ In view of the voluminous nature of references [list as appropriate], and						
	the likelihood that these references are available to the Examiner, copie						
	are not enclosed herewith.						

In accordance with §1.98(d), copies of the following references listed on
the attached Form PTO-1449 are not enclosed herewith because they were
previously cited by or submitted to the U.S. Patent and Trademark Office
in patent application(s) for which a claim for priority under 35
U.S.C.§120 have been made in the instant application:
Copies of references [list as appropriate] listed on the attached Form
PTO-1449 were previously cited by or submitted to the Patent and
Trademark Office in prior application Serial No. , filed .
☐ If any of the foregoing publications are not available to the
Examiner, Applicant will endeavor to supply copies at the

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

Attached is a copy of the PCT International Search Report dated July 12, 2001 and Invitation to Pay Additional Fees dated June 22, 2001, which indicates the documents considered to be relevant.

There are no listed references which are not in the English language.

Examiner's request.

Date: 13 Aug. 2001

Ellen M. Klann

Registration No. 44,836

Elen M. Klaum

WOODCOCK WASHBURN KURTZ MACKIEWICZ & NORRIS LLP One Liberty Place - 46th Floor Philadelphia, PA 19103 Telephone: (215) 568-3100

Facsimile: (215) 568-3439

© 2000 WWKMN

PRADE TRADE	<u> </u>			Sheet 1 of 2			
& TRAD	Form	PTO-1449 Modified	Docket No. TJU-2415	Serial No. 09/819,248			
	(f Patent and Publications Cited by Applicant everal sheets if necessary)	Applicant Scott A. Waldman, et al.				
		Department of Commerce at and Trademark Office	Filing Date March 27, 2001	Group 1645			
	ОТНЕ	CR DOCUMENTS (Including Autho	r, Title, Date, Pertine	ent Pages, Etc.)			
	AA	Cagir, B., et al., "Guanylyl cyclase C messenger RNA is a biomarker for recurrent stage II colorectal cancer," <i>Am. Soc. Internal Med.</i> , 1999 , <i>131(11)</i> , 805-812					
	AB	Li,Z., et al., "Peptide-regulated guanylate cyclase pathways in rat colon: in situ localization of GCA, GCC, and guanylin mRNA," <i>Am. J. Physiol. Soc.</i> , 1993 , <i>265</i> , G394-G402					
	AC	London, R.M., et al., "Signal transduction pathways via guanylin and uroguanylin in stomach and intestine," <i>Am. J. Physiol. Soc.</i> , 1997 , <i>273</i> , G93-G105					
	AD	Mallo, G.V., et al., "Expression of the <i>Cdx1</i> and <i>Cdx2</i> homeotic genes leads to reduced malignancy in colon cancer-derived cells," <i>J. Biological Chem.</i> , 1998 , 273(22), 14030-14036					
	-						

EXAMINER

DATE CONSIDERED

AUG TRADE	A)					Sheet 2 of 2	
Form PTO-1449 Modified				Docket No. TJU-2415	Serial No. 09/819,248		
List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office				Applicant Scott A. Waldman, et al.			
				Filing Date March 27, 2001	Group 1645		
		U	. S. PATENT D	OCUMENTS			
Examiner Initial		Document No.	Date	Name	Class	Subclass	
	AE	5,601,990	02/11/97	Waldman	435	7.23	
	AF	5,879,656	03/09/99	Waldman	424	149	
	AG	6,130,043	10/10/00	Billing-Medel, et al.	435	6	
				T DOGUMENTS			
Examiner Initial			Date	Country	Translation YES NO		
		Document 110.					
			,				
	_						
				1	1		

EXAMINER

DATE CONSIDERED